Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom National Cancer Research Institute recommendations for monitoring.

Jones AL, Barlow M, Barrett-Lee PJ, Canney PA, Gilmour IM, Robb SD, Plummer CJ, Wardley AM, Verrill MW.

Br J Cancer. 2009 Mar 10;100(5):684-92. doi: 10.1038/sj.bjc.6604909.

2.

Cardiac toxicity of trastuzumab: experience at the Ghent Unversity Hospital, Belgium.

Lamot C, Rottey S, De Backer T, Van Bortel L, Robays H, Van Belle S, Denys H, Cocquyt V.

Acta Clin Belg. 2010 Sep-Oct;65(5):300-4.

PMID:
21128555
3.

Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial.

Procter M, Suter TM, de Azambuja E, Dafni U, van Dooren V, Muehlbauer S, Climent MA, Rechberger E, Liu WT, Toi M, Coombes RC, Dodwell D, Pagani O, Madrid J, Hall M, Chen SC, Focan C, Muschol M, van Veldhuisen DJ, Piccart-Gebhart MJ.

J Clin Oncol. 2010 Jul 20;28(21):3422-8. doi: 10.1200/JCO.2009.26.0463.

PMID:
20530280
4.

Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.

Baselga J, Perez EA, Pienkowski T, Bell R.

Oncologist. 2006;11 Suppl 1:4-12. Review.

5.

Management of trastuzumab-related cardiac dysfunction.

Carver JR.

Prog Cardiovasc Dis. 2010 Sep-Oct;53(2):130-9. doi: 10.1016/j.pcad.2010.07.001. Review.

PMID:
20728700
6.

Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.

Telli ML, Hunt SA, Carlson RW, Guardino AE.

J Clin Oncol. 2007 Aug 10;25(23):3525-33. Review.

PMID:
17687157
8.

Cardiac safety of trastuzumab as adjuvant treatment for Japanese patients with early breast cancer.

Ishihara M, Mukai H, Nagai S, Mukohara T.

Int J Clin Oncol. 2009 Oct;14(5):431-5. doi: 10.1007/s10147-009-0898-z.

PMID:
19856052
9.

Adjuvant trastuzumab therapy for HER2-positive breast cancer.

Jahanzeb M.

Clin Breast Cancer. 2008 Aug;8(4):324-33. doi: 10.3816/CBC.2008.n.037. Review.

PMID:
18757259
10.

Clinical cardiac tolerability of trastuzumab.

Perez EA, Rodeheffer R.

J Clin Oncol. 2004 Jan 15;22(2):322-9. Review.

PMID:
14722042
11.

Role of trastuzumab in the adjuvant treatment of HER2-positive early breast cancer.

Haq B, Geyer CE.

Womens Health (Lond). 2009 Mar;5(2):135-47. doi: 10.2217/17455057.5.2.135. Review.

PMID:
19245352
12.

Cardiac toxicity of trastuzumab in metastatic breast cancer patients previously treated with high-dose chemotherapy: a retrospective study.

Bengala C, Zamagni C, Pedrazzoli P, Matteucci P, Ballestrero A, Da Prada G, Martino M, Rosti G, Danova M, Bregni M, Jovic G, Guarneri V, Maur M, Conte PF; Gruppo Italiano Trapianto Midollo Osseo (GITMO) Group..

Br J Cancer. 2006 Apr 10;94(7):1016-20.

13.

Effect of cardiac dysfunction on treatment outcomes in women receiving trastuzumab for HER2-overexpressing metastatic breast cancer.

Tripathy D, Seidman A, Keefe D, Hudis C, Paton V, Lieberman G.

Clin Breast Cancer. 2004 Oct;5(4):293-8.

PMID:
15507176
14.

Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).

de Azambuja E, Procter MJ, van Veldhuisen DJ, Agbor-Tarh D, Metzger-Filho O, Steinseifer J, Untch M, Smith IE, Gianni L, Baselga J, Jackisch C, Cameron DA, Bell R, Leyland-Jones B, Dowsett M, Gelber RD, Piccart-Gebhart MJ, Suter TM.

J Clin Oncol. 2014 Jul 10;32(20):2159-65. doi: 10.1200/JCO.2013.53.9288.

PMID:
24912899
15.

Efficacy and cardiac safety of adjuvant trastuzumab-based chemotherapy regimens for HER2-positive early breast cancer.

Costa RB, Kurra G, Greenberg L, Geyer CE.

Ann Oncol. 2010 Nov;21(11):2153-60. doi: 10.1093/annonc/mdq096. Review.

PMID:
20351072
16.

Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials.

Viani GA, Afonso SL, Stefano EJ, De Fendi LI, Soares FV.

BMC Cancer. 2007 Aug 8;7:153. Review.

17.

Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.

Tan-Chiu E, Yothers G, Romond E, Geyer CE Jr, Ewer M, Keefe D, Shannon RP, Swain SM, Brown A, Fehrenbacher L, Vogel VG, Seay TE, Rastogi P, Mamounas EP, Wolmark N, Bryant J.

J Clin Oncol. 2005 Nov 1;23(31):7811-9.

PMID:
16258083
18.

The cardiac safety of trastuzumab in the treatment of breast cancer.

Chien AJ, Rugo HS.

Expert Opin Drug Saf. 2010 Mar;9(2):335-46. doi: 10.1517/14740331003627441. Review.

PMID:
20175700
19.

Feasibility and cardiac safety of pegylated liposomal doxorubicin plus trastuzumab in heavily pretreated patients with recurrent HER2-overexpressing metastatic breast cancer.

Andreopoulou E, Gaiotti D, Kim E, Volm M, Oratz R, Freedberg R, Downey A, Vogel CL, Chia S, Muggia F.

Clin Breast Cancer. 2007 Aug;7(9):690-6.

PMID:
17919349
20.

Cardiac toxicity of ErbB2-targeted therapies: what do we know?

Perez EA.

Clin Breast Cancer. 2008 Mar;8 Suppl 3:S114-20. Review.

PMID:
18777950

Supplemental Content

Support Center